Form 4: Longboard Pharmaceuticals Director Exercises and Cashes Out Options Following Merger

Phillip M. Schneider, a director at Longboard Pharmaceuticals, cashed out his vested stock options following the company's merger with a subsidiary of H. Lundbeck A/S.

Summary

• This SEC Form 4 filing details the transaction of Longboard Pharmaceuticals director, Phillip M. Schneider, following the company's merger.
• On December 2, 2024, Longboard Pharmaceuticals merged with a subsidiary of H. Lundbeck A/S.
• As a result of the merger, all unvested stock options held by Mr. Schneider were accelerated and became fully vested.
• Upon vesting, these options were automatically cancelled and converted into cash payments.
• The cash payment was calculated as the difference between $60.00 per share and the original exercise price of the options, multiplied by the number of shares covered by the options.
• Mr. Schneider held options with exercise prices of $3.6232, $4.4, $7.06, and $18.94 per share.
• The total number of shares covered by these options were 25,461, 12,367, 12,500, and 22,500 respectively.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction following a merger, which is generally positive for shareholders who receive a premium for their shares. The sentiment is neutral to positive as it is a standard process.

Industry Context

This transaction is a result of the acquisition of Longboard Pharmaceuticals by H. Lundbeck A/S, which is a common occurrence in the pharmaceutical industry where larger companies acquire smaller firms with promising drug pipelines or technologies.

Comparison to Industry Standards

• Mergers and acquisitions in the pharmaceutical industry often trigger similar vesting and cash-out events for stock options held by employees and directors.
• The $60.00 per share valuation used in this transaction is a common method for determining the value of shares in a merger scenario.
• Similar transactions can be seen in the acquisitions of companies like Array BioPharma by Pfizer, where stock options were also converted to cash based on the acquisition price.

Stakeholder Impact

• Shareholders of Longboard Pharmaceuticals received $60.00 per share as part of the merger.
• Employees and directors with stock options received cash payments for their vested options.

Key Dates

Keywords

Merger, Stock Options, Director Transaction, SEC Form 4, Longboard Pharmaceuticals, H. Lundbeck A/S, Acquisition